GSK plc (GSK)
| Market Cap | 102.53B +14.9% |
| Revenue (ttm) | 44.05B +5.0% |
| Net Income | 6.40B +40.8% |
| EPS | 3.13 +42.6% |
| Shares Out | 4.01B |
| PE Ratio | 16.19 |
| Forward PE | 10.40 |
| Dividend | $1.79 (3.53%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 5,517,658 |
| Open | 49.98 |
| Previous Close | 49.46 |
| Day's Range | 49.77 - 51.12 |
| 52-Week Range | 42.85 - 61.70 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 60.51 (+19.51%) |
| Earnings Date | Oct 28, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for GSK stock is "Buy." The 12-month stock price target is $60.51, which is an increase of 19.51% from the latest price.
News
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
GSK's Jemperli Becomes First Approved Immunotherapy For MSI-H/dMMR Locally Advanced Renal Cancer
(RTTNews) - GSK plc (GSK) announced that the U.S. FDA has approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H) or mismatch rep...
GSK announces FDA approval of Jemperli
GSK (GSK) announced the U.S. FDA has approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high/mismatch repair deficient locally advanced r...
GSK (GSK) Gains FDA Approval for Jemperli, Boosting Outlook for Dividend Investors
GSK (GSK) Gains FDA Approval for Jemperli, Boosting Outlook for Dividend Investors
AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion for Jemperli
AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion for Jemperli
AnaptysBio notes Jemperli approved in U.S. for locally advanced rectal cancer
AnaptysBio (ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK (GSK) company, and Quimilza with Vanda, announced that GSK has received U.S. Food and…
GSK confirms FDA approval of Jemperli for certain rectal cancers
GSK (GSK) announced the Food and Drug Administration has approved Jemperli as “the first and only immunotherapy” for adults with stage II and III microsatellite instability-high/mismatch repair defici...
GSK Reveals Positive Early Data For Ris-Rez In Extensive-stage Small Cell Lung Cancer
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Monday the first global data for risvutatug rezetecan (Ris-Rez), its investigational B7-H3-targeted antibody-drug conjugate (ADC), in pati...
GSK (GSK) Reports Promising Phase Ib Data for Risvutatug Rezetecan in Small Cell Lung Cancer
GSK (GSK) Reports Promising Phase Ib Data for Risvutatug Rezetecan in Small Cell Lung Cancer
GSK announces global data for risvutatug rezetecan
GSK (GSK) announced the first global data for risvutatug rezetecan, its investigational B7-H3-targeted antibody-drug conjugate, in patients with relapsed extensive-stage small cell lung cancer, ES-SCL...
Belgian Minister To Closely Monitor GSK Restructuring Plan
(RTTNews) - On October 14, The Belgian government has pledged to closely monitor the restructuring plans announced by GSK plc. (GSK), with David Clarinval, Belgium's Deputy Prime Minister and Minister...
GSK PLC (GSK) Shares Surge 3.5% -- What GF Score of 77 Tells Investors
GSK PLC (GSK) Shares Surge 3.5% -- What GF Score of 77 Tells Investors
GSK Plans Major Restructuring in Belgium, Impacting Over 1,200 Jobs (Ticker: GSK)
GSK Plans Major Restructuring in Belgium, Impacting Over 1,200 Jobs (Ticker: GSK)
GSK (GSK) Plans Workforce Reduction in Belgium Amid Restructuring Efforts
GSK (GSK) Plans Workforce Reduction in Belgium Amid Restructuring Efforts
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big p...
GSK Commits $800M to Pennsylvania Expansion, Supporting Dividend Sustainability (Ticker: GSK)
GSK Commits $800M to Pennsylvania Expansion, Supporting Dividend Sustainability (Ticker: GSK)
Pennsylvania Governor announces $800M investment from GSK in biopharma hub
Pennsylvania Governor Josh Shapiro and Department of Community and Economic Development, DCED, Secretary Rick Siger announced the Commonwealth has secured an over $800M investment from global biopharm...
GSK (GSK) Commits $800M+ to Expand Biologics Manufacturing in Pennsylvania
GSK (GSK) Commits $800M+ to Expand Biologics Manufacturing in Pennsylvania
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs
GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, ...
Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with GSK.
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
For the first time, Viola Davis shares her experience with shingles Viola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come ...
ViiV Healthcare's Positive Cabenuva Trial Boosts GSK (GSK) Outlook Amid Solid Dividend Profile
ViiV Healthcare's Positive Cabenuva Trial Boosts GSK (GSK) Outlook Amid Solid Dividend Profile
GSK’s ViiV Healthcare announces phase IIIb CROWN study met primary endpoint
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced the phase IIIb CROWN study met its primary endpoint, demonstrating that at…
Pre-Market Most Active for Oct 1, 2026 : SQQQ, TQQQ, INTC, MUU, TLT, GSK, NVDA, ACN, CTVA, NOK, SGOV, INFY
The NASDAQ 100 Pre-Market Indicator is up 170.98 to 30,579.48. The total Pre-Market volume is currently 137,328,934 shares traded.The following are the most active stocks for the pre-market session: P...